Anti-Human CGRP1  Reference Antibody (Fremanezumab, RUO)

Description: Fremanezumab (BS10630) is a research-grade recombinant antibody targeting CCP. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG2-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CCP,PDN-21,CALCA,Calcitonincarboxyl-terminalpeptide,Calcitonin,CALC1,Calcitoningene-relatedpeptideII,CALCB,Calcitoningene-relatedpeptide2,Beta-CGRP,CALC2,CGRP-II,Beta-typeCGRP
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: LBR-101,PF-04427429,RI-307,RN-307,TEV-48125,fremanezumab-vfrm,CAS:1655501-53-3
Background: Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.
Note: For research use only. Not suitable for clinical or therapeutic use.